Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLSNASDAQ:HCMNASDAQ:MORNASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$12.08+2.4%$11.98$8.67▼$17.82$778.81M1.11666,727 shs957,476 shsHCMHUTCHMED$15.00+1.4%$14.91$11.51▼$21.92$2.58B0.55105,736 shs94,833 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APTGXProtagonist Therapeutics$45.51+1.2%$46.37$25.23▼$60.60$2.79B2.3860,812 shs644,080 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus+2.37%+3.69%-1.15%-13.53%-4.28%HCMHUTCHMED+1.35%+2.67%-5.66%+10.95%-20.04%MORMorphoSys0.00%0.00%0.00%0.00%+8.28%PTGXProtagonist Therapeutics+1.16%+2.29%-5.58%+20.40%+78.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOLSEvolus3.8638 of 5 stars3.51.00.03.52.92.50.6HCMHUTCHMED1.8184 of 5 stars3.02.00.00.01.30.01.9MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics3.5021 of 5 stars4.51.00.00.03.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 3.00Buy$23.7596.61% UpsideHCMHUTCHMED 2.00Hold$19.0026.67% UpsideMORMorphoSys 0.00N/AN/AN/APTGXProtagonist Therapeutics 3.00Buy$65.4443.80% UpsideCurrent Analyst Ratings BreakdownLatest EOLS, MOR, PTGX, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/28/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/11/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.003/11/2025PTGXProtagonist TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $76.003/11/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$62.00 ➝ $72.003/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/5/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$266.27M2.92N/AN/A($0.36) per share-33.56HCMHUTCHMED$630.20M4.15$0.61 per share24.51$4.27 per share3.51MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PTGXProtagonist Therapeutics$434.43M6.43N/AN/A$5.84 per share7.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$61.69M-$0.81N/AN/AN/A-22.33%-847.60%-22.15%5/7/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.0010.27N/AN/AN/AN/A5/9/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APTGXProtagonist Therapeutics-$78.96M$4.2017.11N/AN/A52.76%34.68%30.98%5/6/2025 (Estimated)Latest EOLS, MOR, PTGX, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025EOLSEvolus-$0.04N/AN/AN/A$73.06 millionN/A5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50N/AN/AN/A$30.44 millionN/A2/21/2025Q4 2024PTGXProtagonist Therapeutics-$0.09$1.98+$2.07$1.98$56.65 million$170.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolus20.582.472.23HCMHUTCHMED0.072.812.68MORMorphoSys4.981.381.38PTGXProtagonist TherapeuticsN/A10.6910.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%HCMHUTCHMED8.82%MORMorphoSys18.38%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipEOLSEvolus6.10%HCMHUTCHMED3.60%MORMorphoSys0.05%PTGXProtagonist Therapeutics5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17064.47 million59.46 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePTGXProtagonist Therapeutics12061.38 million56.38 millionOptionableEOLS, MOR, PTGX, and HCM HeadlinesRecent News About These CompaniesTwo Sigma Securities LLC Invests $212,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 3 at 4:59 AM | marketbeat.comBoothbay Fund Management LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 2 at 5:12 AM | marketbeat.comProtagonist Therapeutics (PTGX) Projected to Post Earnings on TuesdayMay 1 at 10:18 AM | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Price T Rowe Associates Inc. MDMay 1 at 5:11 AM | marketbeat.comBrokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44April 30 at 2:09 AM | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Artia Global Partners LPApril 29, 2025 | marketbeat.comWells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 29, 2025 | marketbeat.comXTX Topco Ltd Trims Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 28, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from AnalystsApril 27, 2025 | marketbeat.comGuggenheim Capital LLC Has $736,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 27, 2025 | marketbeat.comEversept Partners LP Has $26.20 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,756 SharesApril 24, 2025 | insidertrades.comPeak6 LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 24, 2025 | marketbeat.comProtagonist Therapeutics Stock Short Interest Report | NASDAQ:PTGX | BenzingaApril 20, 2025 | benzinga.comRenaissance Technologies LLC Buys 77,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 20, 2025 | marketbeat.comInvesco Ltd. Acquires 85,800 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 20, 2025 | marketbeat.comCapital Fund Management S.A. Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 18, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Up 6.1% - Should You Buy?April 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 17, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)April 17, 2025 | marketbeat.comProtagonist Therapeutics Reports Granting of Inducement AwardApril 16, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Breaks Down But RSI Signals It’s Severely OversoldBy Sam Quirke | April 8, 2025View Qualcomm Breaks Down But RSI Signals It’s Severely OversoldBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?By Jea Yu | April 4, 2025View Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?Top 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketGold Is Making All-Time Highs, But So Is This Quiet MetalBy Gabriel Osorio-Mazilli | April 21, 2025View Gold Is Making All-Time Highs, But So Is This Quiet MetalJPMorgan Is a Buy, If You Can Handle The Volatility By Thomas Hughes | April 11, 2025View JPMorgan Is a Buy, If You Can Handle The Volatility EOLS, MOR, PTGX, and HCM Company DescriptionsEvolus NASDAQ:EOLS$12.08 +0.28 (+2.37%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.75 -0.33 (-2.73%) As of 05/2/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.HUTCHMED NASDAQ:HCM$15.00 +0.20 (+1.35%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$14.99 -0.01 (-0.07%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/2/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Protagonist Therapeutics NASDAQ:PTGX$45.51 +0.52 (+1.16%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$45.51 0.00 (0.00%) As of 05/2/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
